Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

K, Takezawa; I, Okamoto; K, Yonesaka; E, Hatashita; Y, Yamada; M, Fukuoka; K, Nakagawa

doi:10.1158/0008-5472.can-09-1076

Public

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

Shared by NobleBlocks on Jul 28, 2009 • 12:00 AM UTC

Authors:

Takezawa K

Okamoto I

Yonesaka K

Abstract

Sorafenib is a multikinase inhibitor whose targets include B-RAF and C-RAF, both of which function in the extracellular signal-regulated kinase (ERK) signaling pathway but which also have distinct downstream targets. The relative effects of sorafenib on B-RAF and C-RAF signaling in tumor cells remai...

Discussions